MX2022007902A - Metodos para predecir la utilidad de proteinas o fragmentos de proteina para inmunoterapia. - Google Patents
Metodos para predecir la utilidad de proteinas o fragmentos de proteina para inmunoterapia.Info
- Publication number
- MX2022007902A MX2022007902A MX2022007902A MX2022007902A MX2022007902A MX 2022007902 A MX2022007902 A MX 2022007902A MX 2022007902 A MX2022007902 A MX 2022007902A MX 2022007902 A MX2022007902 A MX 2022007902A MX 2022007902 A MX2022007902 A MX 2022007902A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- immunotherapy
- predicting
- usefulness
- proteins
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 4
- 238000009169 immunotherapy Methods 0.000 title abstract 3
- 102000004169 proteins and genes Human genes 0.000 title 2
- 108090000623 proteins and genes Proteins 0.000 title 2
- 239000012634 fragment Substances 0.000 title 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 4
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 4
- 206010028980 Neoplasm Diseases 0.000 abstract 3
- 229920001184 polypeptide Polymers 0.000 abstract 2
- 238000002255 vaccination Methods 0.000 abstract 2
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 238000009566 cancer vaccine Methods 0.000 abstract 1
- 229940022399 cancer vaccine Drugs 0.000 abstract 1
- 230000002163 immunogen Effects 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6878—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids in epitope analysis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5035—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on sub-cellular localization
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
- G01N33/56977—HLA or MHC typing
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4712—Muscle proteins, e.g. myosin, actin, protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Oncology (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
La presente invención se relaciona con métodos para predecir péptidos o polipéptidos como epítopos de células T útiles para inmunoterapia como para vacunación. En particular, la presente invención se relación con métodos para predecir si péptidos o polipéptidos como antígenos o epítopos asociados con un tumor, en particular neoantígenos o neoepitopos asociados con un tumor, son inmunogénicos y, en particular, útiles para inmunoterapia como para vacunación. Los métodos de la invención pueden ser usados, en particular, para proporcionar vacunas las cuales son específicas para un tumor de paciente y, de este modo, en el contexto de vacunas contra el cáncer personalizadas.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2016/060897 WO2017194170A1 (en) | 2016-05-13 | 2016-05-13 | Methods for predicting the usefulness of proteins or protein fragments for immunotherapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022007902A true MX2022007902A (es) | 2022-07-21 |
Family
ID=55971007
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018013081A MX393653B (es) | 2016-05-13 | 2017-05-10 | Metodos para predecir la utilidad de proteinas o fragmentos de proteina para inmunoterapia |
| MX2022007902A MX2022007902A (es) | 2016-05-13 | 2018-10-25 | Metodos para predecir la utilidad de proteinas o fragmentos de proteina para inmunoterapia. |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018013081A MX393653B (es) | 2016-05-13 | 2017-05-10 | Metodos para predecir la utilidad de proteinas o fragmentos de proteina para inmunoterapia |
Country Status (27)
| Country | Link |
|---|---|
| US (2) | US12153041B2 (es) |
| EP (3) | EP4411376A3 (es) |
| JP (5) | JP7529381B2 (es) |
| KR (3) | KR20220020993A (es) |
| CN (1) | CN109073637A (es) |
| AU (2) | AU2017264546B2 (es) |
| BR (1) | BR112018073221A2 (es) |
| CA (1) | CA3022654A1 (es) |
| CY (1) | CY1123520T1 (es) |
| DK (2) | DK3792628T3 (es) |
| ES (2) | ES2826480T3 (es) |
| FI (1) | FI3792628T3 (es) |
| HR (2) | HRP20240704T1 (es) |
| HU (2) | HUE067497T2 (es) |
| IL (2) | IL300841A (es) |
| LT (2) | LT3455625T (es) |
| MA (1) | MA43794B1 (es) |
| MD (1) | MD3455625T2 (es) |
| MX (2) | MX393653B (es) |
| PL (2) | PL3455625T3 (es) |
| PT (2) | PT3792628T (es) |
| RS (2) | RS65568B1 (es) |
| SG (1) | SG11201808495SA (es) |
| SI (2) | SI3792628T1 (es) |
| SM (2) | SMT202400232T1 (es) |
| WO (2) | WO2017194170A1 (es) |
| ZA (1) | ZA201805809B (es) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL260030B2 (en) | 2016-01-08 | 2025-12-01 | Nykode Therapeutics ASA | Therapeutic anticancer neoepitope vaccine |
| WO2017194170A1 (en) | 2016-05-13 | 2017-11-16 | Biontech Rna Pharmaceuticals Gmbh | Methods for predicting the usefulness of proteins or protein fragments for immunotherapy |
| EP3933408A1 (en) | 2017-05-30 | 2022-01-05 | Nant Holdings IP LLC | Circulating tumor cell enrichment using neoepitopes |
| JP6857930B2 (ja) * | 2018-02-15 | 2021-04-14 | 国立大学法人旭川医科大学 | がん抗原ペプチド |
| CA3106564A1 (en) | 2018-07-26 | 2020-01-30 | Frame Pharmaceuticals B.V. | Cancer vaccines for breast cancer |
| US20220349010A1 (en) | 2018-07-26 | 2022-11-03 | Frame Pharmaceuticals B.V. | Method of preparing subject-specific immunogenic compositions based on a neo open-reading-frame peptide database |
| CN109021062B (zh) * | 2018-08-06 | 2021-08-20 | 倍而达药业（苏州）有限公司 | 一种肿瘤新抗原的筛选方法 |
| CN111621564B (zh) * | 2019-02-28 | 2022-03-25 | 武汉大学 | 一种鉴定有效肿瘤新抗原的方法 |
| TWI894138B (zh) * | 2019-03-06 | 2025-08-21 | 美商西雅圖項目公司 | 利用ii 類mhc 模型鑑別新抗原 |
| CN110534156B (zh) * | 2019-09-02 | 2022-06-17 | 深圳市新合生物医疗科技有限公司 | 一种提取免疫治疗新抗原的方法及系统 |
| CN111487399B (zh) * | 2020-03-26 | 2021-09-17 | 湖南师范大学 | 一种蛋白分子标记在鱼类生殖细胞发育研究中的应用 |
| WO2023025404A1 (en) | 2021-08-24 | 2023-03-02 | BioNTech SE | In vitro transcription technologies |
| WO2024083345A1 (en) | 2022-10-21 | 2024-04-25 | BioNTech SE | Methods and uses associated with liquid compositions |
| WO2025202937A1 (en) | 2024-03-26 | 2025-10-02 | BioNTech SE | Cancer vaccines |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2766205B1 (fr) * | 1997-07-16 | 2002-08-30 | Inst Nat Sante Rech Med | Nouveau procede de sensibilisation de cellules presentatrices d'antigene et nouveaux moyens pour la mise en oeuvre du procede |
| DK1276896T3 (da) * | 2000-04-28 | 2010-10-18 | Mannkind Corp | Epitop-synkronisering i antigen-præsenterende celler |
| CA2415902A1 (en) | 2000-07-10 | 2002-01-17 | Xencor | Protein design automation for designing protein libraries with altered immunogenicity |
| JP4900884B2 (ja) * | 2000-07-31 | 2012-03-21 | 株式会社グリーンペプタイド | 腫瘍抗原 |
| DE10225139A1 (de) | 2002-05-29 | 2004-02-26 | Immatics Biotechnologies Gmbh | Verfahren zur Identifizierung von immunreaktiven Peptiden |
| TW200413539A (en) * | 2002-09-30 | 2004-08-01 | Oncotherapy Science Inc | Genes and polypeptides relating to prostate cancers |
| WO2006105255A2 (en) * | 2005-03-29 | 2006-10-05 | The Board Of Trustees Of The University Of Illinois | Cancer vaccines and therapeutic methods |
| JP2009273377A (ja) * | 2008-05-12 | 2009-11-26 | Igaku Seibutsugaku Kenkyusho:Kk | Ｍｈｃクラスｉ分子と結合し癌細胞の表面に表出されるペプチド候補の選択方法 |
| TW201000119A (en) * | 2008-06-10 | 2010-01-01 | Oncotherapy Science Inc | MYBL2 epitope peptides and vaccines containing the same |
| RS53782B1 (sr) * | 2008-10-01 | 2015-06-30 | Immatics Biotechnologies Gmbh | Preparati tumor-asociranih peptida i odgovarajuća antikancerska vakcina za tretman glioblastoma (gbm) i drugih kancera |
| CA2755983A1 (en) | 2009-03-23 | 2010-09-30 | The Walter And Eliza Hall Institute Of Medical Research | Compounds and methods for modulating an immune response |
| AU2010310468A1 (en) * | 2009-10-23 | 2012-05-24 | Mannkind Corporation | Cancer immunotherapy and method of treatment |
| PL3892295T3 (pl) | 2011-05-24 | 2023-07-24 | BioNTech SE | Zindywidualizowane szczepionki przeciwnowotworowe |
| WO2012159643A1 (en) | 2011-05-24 | 2012-11-29 | Biontech Ag | Individualized vaccines for cancer |
| EP2714730A1 (en) * | 2011-06-01 | 2014-04-09 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Novel antigen peptide and uses thereof |
| GB201319446D0 (en) | 2013-11-04 | 2013-12-18 | Immatics Biotechnologies Gmbh | Personalized immunotherapy against several neuronal and brain tumors |
| ES2970865T3 (es) | 2015-12-16 | 2024-05-31 | Gritstone Bio Inc | Identificación, fabricación y uso de neoantígenos |
| WO2017194170A1 (en) | 2016-05-13 | 2017-11-16 | Biontech Rna Pharmaceuticals Gmbh | Methods for predicting the usefulness of proteins or protein fragments for immunotherapy |
| CA3060569A1 (en) | 2017-04-19 | 2018-10-25 | Gritstone Oncology, Inc. | Neoantigen identification, manufacture, and use |
| AU2018279627B2 (en) | 2017-06-09 | 2023-08-10 | Seattle Project Corp. | Neoantigen identification, manufacture, and use |
| US20200363414A1 (en) | 2017-09-05 | 2020-11-19 | Gritstone Oncology, Inc. | Neoantigen Identification for T-Cell Therapy |
| EP4576103A3 (en) | 2017-10-10 | 2025-08-27 | Gritstone bio, Inc. | Neoantigen identification using hotspots |
| CN111630602A (zh) | 2017-11-22 | 2020-09-04 | 磨石肿瘤生物技术公司 | 减少新抗原的接合表位呈递 |
| EP3759131A4 (en) | 2018-02-27 | 2021-12-01 | Gritstone bio, Inc. | NEOANTIGEN IDENTIFICATION WITH PAN ALLELE MODELS |
-
2016
- 2016-05-13 WO PCT/EP2016/060897 patent/WO2017194170A1/en not_active Ceased
-
2017
- 2017-05-10 EP EP24171718.0A patent/EP4411376A3/en active Pending
- 2017-05-10 HU HUE20193183A patent/HUE067497T2/hu unknown
- 2017-05-10 MA MA43794A patent/MA43794B1/fr unknown
- 2017-05-10 MD MDE20190332T patent/MD3455625T2/ro unknown
- 2017-05-10 PT PT201931839T patent/PT3792628T/pt unknown
- 2017-05-10 MX MX2018013081A patent/MX393653B/es unknown
- 2017-05-10 BR BR112018073221-4A patent/BR112018073221A2/pt unknown
- 2017-05-10 JP JP2018559794A patent/JP7529381B2/ja active Active
- 2017-05-10 WO PCT/EP2017/061196 patent/WO2017194610A1/en not_active Ceased
- 2017-05-10 HU HUE17726208A patent/HUE052240T2/hu unknown
- 2017-05-10 LT LTEP17726208.6T patent/LT3455625T/lt unknown
- 2017-05-10 HR HRP20240704TT patent/HRP20240704T1/hr unknown
- 2017-05-10 FI FIEP20193183.9T patent/FI3792628T3/fi active
- 2017-05-10 ES ES17726208T patent/ES2826480T3/es active Active
- 2017-05-10 KR KR1020227002915A patent/KR20220020993A/ko not_active Ceased
- 2017-05-10 EP EP17726208.6A patent/EP3455625B1/en active Active
- 2017-05-10 AU AU2017264546A patent/AU2017264546B2/en active Active
- 2017-05-10 SG SG11201808495SA patent/SG11201808495SA/en unknown
- 2017-05-10 RS RS20240614A patent/RS65568B1/sr unknown
- 2017-05-10 US US16/301,019 patent/US12153041B2/en active Active
- 2017-05-10 PT PT177262086T patent/PT3455625T/pt unknown
- 2017-05-10 CN CN201780026579.0A patent/CN109073637A/zh active Pending
- 2017-05-10 DK DK20193183.9T patent/DK3792628T3/da active
- 2017-05-10 HR HRP20201671TT patent/HRP20201671T1/hr unknown
- 2017-05-10 SM SM20240232T patent/SMT202400232T1/it unknown
- 2017-05-10 IL IL300841A patent/IL300841A/en unknown
- 2017-05-10 PL PL17726208T patent/PL3455625T3/pl unknown
- 2017-05-10 KR KR1020187032652A patent/KR102358620B1/ko active Active
- 2017-05-10 RS RS20201233A patent/RS61071B1/sr unknown
- 2017-05-10 DK DK17726208.6T patent/DK3455625T3/da active
- 2017-05-10 ES ES20193183T patent/ES2980781T3/es active Active
- 2017-05-10 PL PL20193183.9T patent/PL3792628T3/pl unknown
- 2017-05-10 SI SI201731526T patent/SI3792628T1/sl unknown
- 2017-05-10 EP EP20193183.9A patent/EP3792628B1/en active Active
- 2017-05-10 LT LTEP20193183.9T patent/LT3792628T/lt unknown
- 2017-05-10 SI SI201730466T patent/SI3455625T1/sl unknown
- 2017-05-10 CA CA3022654A patent/CA3022654A1/en active Pending
- 2017-05-10 KR KR1020247031632A patent/KR20240146087A/ko active Pending
- 2017-05-10 SM SM20200622T patent/SMT202000622T1/it unknown
-
2018
- 2018-08-29 ZA ZA2018/05809A patent/ZA201805809B/en unknown
- 2018-10-25 MX MX2022007902A patent/MX2022007902A/es unknown
- 2018-10-29 IL IL262680A patent/IL262680B2/en unknown
-
2020
- 2020-10-14 CY CY20201100969T patent/CY1123520T1/el unknown
-
2022
- 2022-02-16 JP JP2022021751A patent/JP2022081492A/ja active Pending
- 2022-07-27 AU AU2022209286A patent/AU2022209286A1/en active Pending
-
2024
- 2024-03-21 JP JP2024045130A patent/JP2024096712A/ja active Pending
- 2024-04-23 JP JP2024069742A patent/JP2024112805A/ja active Pending
- 2024-06-27 JP JP2024103724A patent/JP2024160216A/ja active Pending
- 2024-10-18 US US18/920,525 patent/US20250244311A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022007902A (es) | Metodos para predecir la utilidad de proteinas o fragmentos de proteina para inmunoterapia. | |
| MX2022000012A (es) | Prediccion de epitopos de celulas t utiles para vacunacion. | |
| MX2024006356A (es) | Metodos para predecir la utilidad de modificaciones de aminoacidos especificas de una enfermedad para inmunoterapia | |
| CY1124176T1 (el) | Προβλεψη ανοσογονiκοτητας των επιτοπων των t κυτταρων | |
| EA202191027A3 (ru) | Новые пептиды и комбинации пептидов для применения в иммунотерапии нескольких видов опухолей | |
| PH12017501275A1 (en) | Novel peptides and combination of peptides for use in immunotherapy against lung cancer, including nsclc and other cancers | |
| EA201992664A3 (ru) | Новые пептиды и комбинации пептидов для применения в иммунотерапии рака яичника и других видов рака | |
| MX2017014008A (es) | Nuevos peptidos y nuevas combinaciones de peptidos y de soportes para el uso en la inmunoterapia contra el carcinoma colorrectal y otros tipos de cancer. | |
| EA201791150A1 (ru) | Новые пептиды и комбинации пептидов для применения в иммунотерапии гепатоклеточной карциномы (гкк) и других видов рака | |
| PH12019500313A1 (en) | Novel peptides and scaffolds for use in immunotherapy against head and neck squamous cell carcinoma and other cancers | |
| PH12017501994A1 (en) | Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (crc) and other cancers | |
| EA202190465A3 (ru) | Новые пептиды и комбинации пептидов для применения в иммунотерапии нхл и других видов рака | |
| EA201990588A1 (ru) | Новые пептиды и каркасы для применения в иммунотерапии плоскоклеточной карциномы головы и шеи и других видов рака | |
| EA202091863A2 (ru) | Новые пептиды и комбинации пептидов для применения в иммунотерапии рака легких, в том числе немелкоклеточного рака легких (нмрл) и других видов рака | |
| EA202190357A2 (ru) | Новые пептиды и комбинации пептидов для применения в иммунотерапии нескольких видов рака | |
| MY197511A (en) | Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (crc) and other cancers | |
| MY198517A (en) | Novel peptides and combination of peptides for use in immunotherapy against lung cancer, including nsclc and other cancers |